PL194025B1
(pl)
|
1996-10-18 |
2007-04-30 |
Vertex Pharma |
Inhibitory proteaz serynowych, a zwłaszcza proteazy wirusa NS3 zapalenia wątroby C, kompozycja farmaceutyczna i zastosowanie inhibitorów proteaz serynowych
|
GB9707659D0
(en)
*
|
1997-04-16 |
1997-06-04 |
Peptide Therapeutics Ltd |
Hepatitis C NS3 Protease inhibitors
|
DE69827956T2
(de)
*
|
1997-08-11 |
2005-04-14 |
Boehringer Ingelheim (Canada) Ltd., Laval |
Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
|
CA2294049A1
(fr)
*
|
1997-08-11 |
1999-02-18 |
Boehringer Ingelheim (Canada) Ltd. |
Peptides inhibiteurs de l'hepatite c
|
US6767991B1
(en)
|
1997-08-11 |
2004-07-27 |
Boehringer Ingelheim (Canada) Ltd. |
Hepatitis C inhibitor peptides
|
GB9806815D0
(en)
*
|
1998-03-30 |
1998-05-27 |
Hoffmann La Roche |
Amino acid derivatives
|
AU3376699A
(en)
*
|
1998-03-31 |
1999-10-18 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
|
GB9809664D0
(en)
|
1998-05-06 |
1998-07-01 |
Hoffmann La Roche |
a-Ketoamide derivatives
|
GB9812523D0
(en)
|
1998-06-10 |
1998-08-05 |
Angeletti P Ist Richerche Bio |
Peptide inhibitors of hepatitis c virus ns3 protease
|
US6323180B1
(en)
|
1998-08-10 |
2001-11-27 |
Boehringer Ingelheim (Canada) Ltd |
Hepatitis C inhibitor tri-peptides
|
AR022061A1
(es)
*
|
1998-08-10 |
2002-09-04 |
Boehringer Ingelheim Ca Ltd |
Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
|
EP1159273A1
(fr)
|
1999-03-02 |
2001-12-05 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Composes utiles en tant qu'inhibiteurs reversibles de la cathepsine s
|
UA74546C2
(en)
*
|
1999-04-06 |
2006-01-16 |
Boehringer Ingelheim Ca Ltd |
Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
|
US6608027B1
(en)
|
1999-04-06 |
2003-08-19 |
Boehringer Ingelheim (Canada) Ltd |
Macrocyclic peptides active against the hepatitis C virus
|
AU5920400A
(en)
*
|
1999-07-07 |
2001-01-22 |
Du Pont Pharmaceuticals Company |
Cell-based assay systems for examining hcv ns3 protease activity
|
US7122627B2
(en)
|
1999-07-26 |
2006-10-17 |
Bristol-Myers Squibb Company |
Lactam inhibitors of Hepatitis C virus NS3 protease
|
AU6371900A
(en)
*
|
1999-07-26 |
2001-02-13 |
Du Pont Pharmaceuticals Company |
Lactam inhibitors of hepatitis c virus ns3 protease
|
US6420364B1
(en)
|
1999-09-13 |
2002-07-16 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Compound useful as reversible inhibitors of cysteine proteases
|
US7026469B2
(en)
|
2000-10-19 |
2006-04-11 |
Wake Forest University School Of Medicine |
Compositions and methods of double-targeting virus infections and cancer cells
|
JP2003526634A
(ja)
*
|
1999-12-03 |
2003-09-09 |
ブリストル−マイヤーズ スクイブ ファーマ カンパニー |
C型肝炎ウイルスNS3プロテアーゼのα−ケトアミド阻害剤
|
MXPA02005596A
(es)
*
|
1999-12-07 |
2004-09-10 |
Theravance Inc |
Derivados de carbamato con actividad antagonista para el rerceptor muscarinico.
|
WO2001064678A2
(fr)
*
|
2000-02-29 |
2001-09-07 |
Bristol-Myers Squibb Pharma Company |
Inhibiteurs de la protéase ns3 du virus de l'hépatite c
|
AU2006202124B2
(en)
*
|
2000-04-03 |
2010-01-21 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of Serine Proteases, Particularly Hepatitis C Virus NS3 Protease
|
AU2001251165A1
(en)
*
|
2000-04-03 |
2001-10-15 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
|
WO2001077113A2
(fr)
|
2000-04-05 |
2001-10-18 |
Schering Corporation |
Ns3-serine macrocyclique inhibitrice de la protease du virus de l'hepatite c, comprenant des fragments p2 n cycliques
|
PL358591A1
(en)
|
2000-04-19 |
2004-08-09 |
Schering Corporation |
Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising alkyl and aryl alanine p2 moieties
|
PE20011350A1
(es)
|
2000-05-19 |
2002-01-15 |
Vertex Pharma |
PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
|
MY164523A
(en)
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
EP1736478B1
(fr)
|
2000-05-26 |
2015-07-22 |
IDENIX Pharmaceuticals, Inc. |
Procédés et compositions de traitement des flavivirus et des pestivirus
|
US20020007324A1
(en)
*
|
2000-06-09 |
2002-01-17 |
Centner David J. |
System and method for effectively conducting transactions between buyers and suppliers
|
AR034127A1
(es)
*
|
2000-07-21 |
2004-02-04 |
Schering Corp |
Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
|
US7244721B2
(en)
*
|
2000-07-21 |
2007-07-17 |
Schering Corporation |
Peptides as NS3-serine protease inhibitors of hepatitis C virus
|
CN102372764A
(zh)
|
2000-07-21 |
2012-03-14 |
先灵公司 |
用作丙型肝炎病毒ns3-丝氨酸蛋白酶抑制剂的新型肽
|
AR029851A1
(es)
|
2000-07-21 |
2003-07-16 |
Dendreon Corp |
Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
|
MXPA03000626A
(es)
*
|
2000-07-21 |
2004-07-30 |
Schering Corp |
Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de la hepatitis c.
|
SV2003000617A
(es)
*
|
2000-08-31 |
2003-01-13 |
Lilly Co Eli |
Inhibidores de la proteasa peptidomimetica ref. x-14912m
|
ATE338564T1
(de)
*
|
2000-10-12 |
2006-09-15 |
Viromics Gmbh |
Proteasome inhibitoren zur behandlung von hepatitis-virus infektionen
|
PT1411954E
(pt)
|
2000-10-18 |
2011-03-16 |
Pharmasset Inc |
Nucleosídeos modificados para o tratamento de infecções virais e proliferação celular anormal
|
US6846806B2
(en)
|
2000-10-23 |
2005-01-25 |
Bristol-Myers Squibb Company |
Peptide inhibitors of Hepatitis C virus NS3 protein
|
KR20030091946A
(ko)
*
|
2000-12-12 |
2003-12-03 |
쉐링 코포레이션 |
C형 간염 바이러스의 ns3-세린 프로테아제억제제로서의 디아릴 펩티드
|
US6653295B2
(en)
|
2000-12-13 |
2003-11-25 |
Bristol-Myers Squibb Company |
Inhibitors of hepatitis C virus NS3 protease
|
WO2002048157A2
(fr)
*
|
2000-12-13 |
2002-06-20 |
Bristol-Myers Squibb Pharma Company |
Imidazolidinones et leurs derives associes, utiles en tant qu'inhibiteurs des proteases ns3 du virus de l'hepatite c
|
EP1539188B1
(fr)
|
2001-01-22 |
2015-01-07 |
Merck Sharp & Dohme Corp. |
Derives de nucleoside comme inhibiteurs de l'arn polymerase virale arn-dependante
|
JP4455056B2
(ja)
|
2001-07-11 |
2010-04-21 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
架橋二環式セリンプロテアーゼ阻害剤
|
AU2002348414B2
(en)
*
|
2001-10-24 |
2009-10-01 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine protease, particularly hepatitis C virus NS3-NS4A protease, incorporating a fused ring system
|
MY151199A
(en)
*
|
2001-11-02 |
2014-04-30 |
Rigel Pharmaceuticals Inc |
Substituted diphenyl heterocycles useful for treating hcv infection
|
PE20030857A1
(es)
|
2002-01-23 |
2003-10-25 |
Schering Corp |
Compuestos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c
|
US7119072B2
(en)
|
2002-01-30 |
2006-10-10 |
Boehringer Ingelheim (Canada) Ltd. |
Macrocyclic peptides active against the hepatitis C virus
|
US7091184B2
(en)
|
2002-02-01 |
2006-08-15 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
US6642204B2
(en)
|
2002-02-01 |
2003-11-04 |
Boehringer Ingelheim International Gmbh |
Hepatitis C inhibitor tri-peptides
|
SG159385A1
(en)
*
|
2002-04-11 |
2010-03-30 |
Vertex Pharma |
Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease
|
US6869964B2
(en)
|
2002-05-20 |
2005-03-22 |
Bristol-Myers Squibb Company |
Heterocyclicsulfonamide hepatitis C virus inhibitors
|
EP1506172B1
(fr)
*
|
2002-05-20 |
2011-03-30 |
Bristol-Myers Squibb Company |
Inhibiteurs du virus de l'hepatite c
|
EP1505945B1
(fr)
|
2002-05-20 |
2008-11-05 |
Bristol-Myers Squibb Company |
Inhibiteurs du virus de l'hepatite c a base de cycloalkyle p1' substitue
|
MY140680A
(en)
|
2002-05-20 |
2010-01-15 |
Bristol Myers Squibb Co |
Hepatitis c virus inhibitors
|
AU2003247084B9
(en)
|
2002-06-28 |
2018-07-26 |
Centre National De La Recherche Scientifique |
Modified 2' and 3'-nucleoside prodrugs for treating flaviridae infections
|
WO2004026896A2
(fr)
*
|
2002-09-23 |
2004-04-01 |
Medivir Ab |
Inhibiteurs de la serine protease ns-3 du virus de l'hepatite c
|
US20050075279A1
(en)
|
2002-10-25 |
2005-04-07 |
Boehringer Ingelheim International Gmbh |
Macrocyclic peptides active against the hepatitis C virus
|
MXPA05005192A
(es)
|
2002-11-15 |
2005-09-08 |
Idenix Cayman Ltd |
Nucleosidos ramificados en la posicion 2' y mutacion de flaviviridae.
|
CN100453553C
(zh)
|
2003-04-11 |
2009-01-21 |
沃泰克斯药物股份有限公司 |
丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂
|
TW200510391A
(en)
*
|
2003-04-11 |
2005-03-16 |
Vertex Pharma |
Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
|
AU2011203054B2
(en)
*
|
2003-04-11 |
2012-04-26 |
Vertex Pharmaceuticals, Incorporated |
Inhibitors of Serine Proteases, Particularly HCV NS3-NS4A Protease
|
WO2004099165A2
(fr)
|
2003-05-02 |
2004-11-18 |
Rigel Pharmaceuticals, Inc. |
Composes heterocycliques et certains de leurs hydro-isomeres
|
KR101115294B1
(ko)
|
2003-05-21 |
2012-04-12 |
베링거 인겔하임 인터내셔날 게엠베하 |
C형 간염 억제제 화합물
|
CN100503628C
(zh)
|
2003-05-30 |
2009-06-24 |
法莫赛特股份有限公司 |
修饰的氟化核苷类似物
|
EP1646642A2
(fr)
*
|
2003-07-18 |
2006-04-19 |
Vertex Pharmaceuticals Incorporated |
Inhibiteurs de serines proteases, en particulier de la protease ns3-ns4a du vhc
|
AU2004258750A1
(en)
|
2003-07-25 |
2005-02-03 |
Centre National De La Recherche Scientifique -Cnrs |
Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis C
|
US7576206B2
(en)
|
2003-08-14 |
2009-08-18 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
US7223745B2
(en)
|
2003-08-14 |
2007-05-29 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
US7449447B2
(en)
|
2003-08-26 |
2008-11-11 |
Schering Corporation |
Peptidomimetic NS3-serine protease inhibitors of hepatitis C virus
|
MY148123A
(en)
|
2003-09-05 |
2013-02-28 |
Vertex Pharma |
Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
|
JP4685775B2
(ja)
*
|
2003-09-18 |
2011-05-18 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
セリンプロテアーゼ、とりわけhcvns3−ns4aプロテアーゼの阻害剤
|
EA200600498A1
(ru)
|
2003-09-22 |
2006-10-27 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Макроциклические пептиды, проявляющие противовирусную активность в отношении вируса гепатита с
|
US7592419B2
(en)
|
2003-09-26 |
2009-09-22 |
Schering Corporation |
Macrocyclic inhibitors of hepatitis C virus NS3-serine protease
|
NZ546663A
(en)
|
2003-10-10 |
2010-01-29 |
Vertex Pharma |
Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
|
AP2287A
(en)
|
2003-10-14 |
2011-10-31 |
Intermune Inc |
Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication.
|
US8187874B2
(en)
|
2003-10-27 |
2012-05-29 |
Vertex Pharmaceuticals Incorporated |
Drug discovery method
|
ES2389201T3
(es)
|
2003-10-27 |
2012-10-24 |
Vertex Pharmaceuticals Incorporated |
Mutantes de resistencia de la proteasa NS3/4A de HCV
|
EP1944042A1
(fr)
|
2003-10-27 |
2008-07-16 |
Vertex Pharmceuticals Incorporated |
Combinaisons pour le traitement HCV
|
US7132504B2
(en)
|
2003-11-12 |
2006-11-07 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7309708B2
(en)
|
2003-11-20 |
2007-12-18 |
Birstol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7135462B2
(en)
|
2003-11-20 |
2006-11-14 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
CA2546290A1
(fr)
|
2003-11-20 |
2005-06-09 |
Schering Corporation |
Inhibiteurs depourvus de liaisons peptidiques de la protease ns3 du virus de l'hepatite c
|
GB0500020D0
(en)
|
2005-01-04 |
2005-02-09 |
Novartis Ag |
Organic compounds
|
ES2358333T3
(es)
|
2004-01-21 |
2011-05-09 |
Boehringer Ingelheim International Gmbh |
Péptidos macrocíclicos con acción contra el virus de la hepatitis c.
|
CA2552319C
(fr)
|
2004-01-30 |
2012-08-21 |
Medivir Ab |
Inhibiteurs de la ns-3 serine protease du vhc
|
EP1711515A2
(fr)
*
|
2004-02-04 |
2006-10-18 |
Vertex Pharmaceuticals Incorporated |
Inhibiteurs de proteases serines, en particulier de la protease hcv ns3-ns4a
|
US20070049593A1
(en)
|
2004-02-24 |
2007-03-01 |
Japan Tobacco Inc. |
Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
|
JP4143669B2
(ja)
|
2004-02-24 |
2008-09-03 |
日本たばこ産業株式会社 |
4環縮合複素環化合物及びそのhcvポリメラーゼ阻害剤としての利用
|
DE602005023224D1
(de)
|
2004-02-27 |
2010-10-07 |
Schering Corp |
Neuartige Verbindungen als Hemmer von Hepatitis C-Virus NS3-Serinprotease
|
BRPI0508095A
(pt)
|
2004-02-27 |
2007-07-17 |
Schering Corp |
compostos como inibidores de ns3 serina protease do vìrus da hepatite c
|
US7816326B2
(en)
|
2004-02-27 |
2010-10-19 |
Schering Corporation |
Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
|
CA2557322A1
(fr)
|
2004-02-27 |
2005-09-15 |
Schering Corporation |
Inhibiteurs de la protease ns3 du virus de l'hepatite c
|
ES2346233T3
(es)
|
2004-02-27 |
2010-10-13 |
Schering Corporation |
Compuestos de azufre como inhibidores de serina proteasa ns3 del virus de la hepatitis c.
|
PT2399916E
(pt)
*
|
2004-03-12 |
2015-03-17 |
Vertex Pharma |
Processo e intermediários para a preparação de inibidores de caspase de acetal de ácido aspártico
|
AU2005238445B2
(en)
|
2004-04-15 |
2012-05-03 |
Onyx Therapeutics, Inc. |
Compounds for enzyme inhibition
|
US8198270B2
(en)
*
|
2004-04-15 |
2012-06-12 |
Onyx Therapeutics, Inc. |
Compounds for proteasome enzyme inhibition
|
ES2510840T3
(es)
*
|
2004-05-10 |
2014-10-21 |
Onyx Therapeutics, Inc. |
Compuestos para la inhibición enzimática del proteosoma
|
CN1984922A
(zh)
|
2004-05-20 |
2007-06-20 |
先灵公司 |
用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的取代脯氨酸
|
ATE516293T1
(de)
*
|
2004-07-16 |
2011-07-15 |
Gilead Sciences Inc |
Antivirale verbindungen
|
UY29016A1
(es)
|
2004-07-20 |
2006-02-24 |
Boehringer Ingelheim Int |
Analogos de dipeptidos inhibidores de la hepatitis c
|
JP4914355B2
(ja)
|
2004-07-20 |
2012-04-11 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
C型肝炎インヒビターペプチド類似体
|
US7597884B2
(en)
*
|
2004-08-09 |
2009-10-06 |
Alios Biopharma, Inc. |
Hyperglycosylated polypeptide variants and methods of use
|
JP2008513356A
(ja)
*
|
2004-08-09 |
2008-05-01 |
アリオス バイオファーマ インク. |
合成高度糖鎖付加プロテアーゼ耐性ポリペプチド変異体、それを使用する経口製剤および方法
|
MX2007002371A
(es)
|
2004-08-27 |
2007-04-23 |
Schering Corp |
Compuestos de acilsulfonamida como inhibidores de la serina proteasa ns3 del virus de la hepatitis c.
|
KR101177590B1
(ko)
|
2004-09-14 |
2012-08-27 |
파마셋 인코포레이티드 |
2'-플루오로-2'-알킬 치환되거나 또는 다른 선택적으로치환된 리보퓨라노실 피리미딘 및 퓨린 및 그 유도체의제조
|
NZ554351A
(en)
|
2004-10-01 |
2010-02-26 |
Vertex Pharma |
HCV NS3-NS4A protease inhibition using VX-950, also known as telaprevir
|
US7659263B2
(en)
|
2004-11-12 |
2010-02-09 |
Japan Tobacco Inc. |
Thienopyrrole compound and use thereof as HCV polymerase inhibitor
|
US7323447B2
(en)
|
2005-02-08 |
2008-01-29 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7468383B2
(en)
|
2005-02-11 |
2008-12-23 |
Cephalon, Inc. |
Proteasome inhibitors and methods of using the same
|
US7592336B2
(en)
|
2005-05-10 |
2009-09-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
CN101218224B
(zh)
|
2005-05-13 |
2013-05-08 |
Viro化学制药公司 |
治疗或预防黄病毒感染的组合物和方法
|
WO2006127289A1
(fr)
*
|
2005-05-20 |
2006-11-30 |
Valeant Research & Development |
Traitement de l'hepatite c (hcv) au moyen de doses sous-therapeutiques de ribavirine
|
WO2006130666A2
(fr)
*
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Medicaments et procedes destines a combiner un inhibiteur de protease hcv et un competiteur akr
|
CA2611155A1
(fr)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Formulations pharmaceutiques et methodes de traitement employant lesdites formulations
|
US20070237818A1
(en)
*
|
2005-06-02 |
2007-10-11 |
Malcolm Bruce A |
Controlled-release formulation of HCV protease inhibitor and methods using the same
|
WO2006130686A2
(fr)
|
2005-06-02 |
2006-12-07 |
Schering Corporation |
Administration d'inhibiteurs de protease du vhc en combinaison avec des aliments pour ameliorer la biodisponibilite
|
AR054778A1
(es)
|
2005-06-17 |
2007-07-18 |
Novartis Ag |
Uso de sangliferina en hcv
|
US7608592B2
(en)
*
|
2005-06-30 |
2009-10-27 |
Virobay, Inc. |
HCV inhibitors
|
US7601686B2
(en)
|
2005-07-11 |
2009-10-13 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP2305695A3
(fr)
|
2005-07-25 |
2011-07-27 |
Intermune, Inc. |
Inhibiteurs macrocycliques de la multiplication du virus de L'Hépatite C
|
PE20070211A1
(es)
|
2005-07-29 |
2007-05-12 |
Medivir Ab |
Compuestos macrociclicos como inhibidores del virus de hepatitis c
|
AU2006274862B2
(en)
|
2005-07-29 |
2012-03-22 |
Medivir Ab |
Macrocyclic inhibitors of hepatitis C virus
|
PE20070210A1
(es)
|
2005-07-29 |
2007-04-16 |
Tibotec Pharm Ltd |
Compuestos macrociclicos como inhibidores del virus de hepatitis c
|
JO2768B1
(en)
|
2005-07-29 |
2014-03-15 |
تيبوتيك فارماسيوتيكالز ليمتد |
Large cyclic inhibitors of hepatitis C virus
|
JP5426164B2
(ja)
|
2005-07-29 |
2014-02-26 |
ヤンセン・アールアンドデイ・アイルランド |
C型肝炎ウイルスの大環式インヒビター
|
AU2006274861B2
(en)
|
2005-07-29 |
2012-11-08 |
Medivir Ab |
Macrocyclic inhibitors of hepatitis C virus
|
EP1913015B1
(fr)
|
2005-07-29 |
2013-12-11 |
Janssen R&D Ireland |
Inhibiteurs macrocycliques du virus de l'hépatite c
|
ES2373685T3
(es)
|
2005-07-29 |
2012-02-07 |
Tibotec Pharmaceuticals |
Inhibidores macrocíclicos del virus de la hepatitis c.
|
MY139988A
(en)
|
2005-07-29 |
2009-11-30 |
Tibotec Pharm Ltd |
Macrocylic inhibitors of hepatitis c virus
|
JP2009503084A
(ja)
*
|
2005-08-01 |
2009-01-29 |
フェノミックス コーポレーション |
C型肝炎セリンプロテアーゼ阻害剤およびその使用
|
JP2009505966A
(ja)
*
|
2005-08-02 |
2009-02-12 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
セリンプロテアーゼのインヒビター
|
US8399615B2
(en)
|
2005-08-19 |
2013-03-19 |
Vertex Pharmaceuticals Incorporated |
Processes and intermediates
|
SI2194043T1
(sl)
*
|
2005-08-19 |
2014-04-30 |
Vertex Pharmaceuticals Incorporated |
Postopki
|
US7964624B1
(en)
|
2005-08-26 |
2011-06-21 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of serine proteases
|
AR055395A1
(es)
|
2005-08-26 |
2007-08-22 |
Vertex Pharma |
Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
|
CN101415705B
(zh)
|
2005-10-11 |
2011-10-26 |
因特蒙公司 |
抑制丙型肝炎病毒复制的化合物和方法
|
CN101304976A
(zh)
*
|
2005-10-11 |
2008-11-12 |
因特蒙公司 |
病毒复制抑制剂
|
US7772183B2
(en)
|
2005-10-12 |
2010-08-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7741281B2
(en)
|
2005-11-03 |
2010-06-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
PL2623113T3
(pl)
|
2005-11-09 |
2018-05-30 |
Onyx Therapeutics, Inc. |
Związek do hamowania enzymu
|
US7705138B2
(en)
|
2005-11-11 |
2010-04-27 |
Vertex Pharmaceuticals Incorporated |
Hepatitis C virus variants
|
EP1951748B1
(fr)
|
2005-11-11 |
2013-07-24 |
Vertex Pharmaceuticals, Inc. |
Variantes du virus de l'hépatite c
|
WO2007078990A2
(fr)
*
|
2005-12-23 |
2007-07-12 |
Zealand Pharma A/S |
Composés modifiés mimétiques de la lysine
|
JP2009524681A
(ja)
*
|
2006-01-27 |
2009-07-02 |
フェノミックス コーポレーション |
C型肝炎ウイルスセリンプロテアーゼインヒビターおよびそのための使用
|
WO2007092616A2
(fr)
*
|
2006-02-09 |
2007-08-16 |
Schering Corporation |
Combinaisons comprenant un ou plusieurs inhibiteurs de protéase du vhc et un ou plusieurs inhibiteurs de polymérase du vhc, et méthodes de traitement associées
|
EP1991229A2
(fr)
|
2006-02-27 |
2008-11-19 |
Vertex Pharmaceuticals Incorporated |
Co-cristaux et compositions pharmaceutiques les comprenant
|
CA2646229A1
(fr)
*
|
2006-03-16 |
2007-09-27 |
Vertex Pharmaceuticals Incorporated |
Inhibiteurs de protease de l'hepatite c deuteres
|
KR101059593B1
(ko)
|
2006-04-11 |
2011-08-25 |
노파르티스 아게 |
Hcv/hiv 억제제 및 이들의 용도
|
US8017612B2
(en)
|
2006-04-18 |
2011-09-13 |
Japan Tobacco Inc. |
Piperazine compound and use thereof as a HCV polymerase inhibitor
|
US7951823B2
(en)
|
2006-05-23 |
2011-05-31 |
Irm Llc |
Compounds and compositions as channel activating protease inhibitors
|
EP2484688B1
(fr)
|
2006-06-19 |
2016-06-08 |
Onyx Therapeutics, Inc. |
Peptide époxycétones destinées à l'inhibition de proteasome
|
WO2008008776A2
(fr)
|
2006-07-11 |
2008-01-17 |
Bristol-Myers Squibb Company |
Inhibiteurs du virus de l'hépatite c
|
EP1886685A1
(fr)
|
2006-08-11 |
2008-02-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Méthodes, utilisations et compositions pour la modulation de la réplication du HCV par activation ou inhibition du récepteur farnesoid X
|
EP2054076A2
(fr)
*
|
2006-08-21 |
2009-05-06 |
United Therapeutics Corporation |
Polytherapie destinée a traiter des infections virales
|
JP2010502184A
(ja)
*
|
2006-08-28 |
2010-01-28 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
プロテアーゼ阻害剤の同定方法
|
US8343477B2
(en)
|
2006-11-01 |
2013-01-01 |
Bristol-Myers Squibb Company |
Inhibitors of hepatitis C virus
|
US7772180B2
(en)
|
2006-11-09 |
2010-08-10 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
JP5290186B2
(ja)
|
2006-11-15 |
2013-09-18 |
ヴァイロケム ファーマ インコーポレイテッド |
フラビウイルス感染症の治療または予防用のチオフェン類似体
|
US7888464B2
(en)
|
2006-11-16 |
2011-02-15 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8003604B2
(en)
|
2006-11-16 |
2011-08-23 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US7763584B2
(en)
|
2006-11-16 |
2010-07-27 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
EP2428204A3
(fr)
|
2006-12-07 |
2012-07-04 |
Schering Corporation |
Formulation de matrice sensible au pH
|
EP2074087A2
(fr)
|
2006-12-21 |
2009-07-01 |
Wyeth |
Synthese de composes de pyrrolidine
|
ATE543808T1
(de)
|
2006-12-22 |
2012-02-15 |
Schering Corp |
5,6-ring-annelierte indolderivate und ihre verwendung
|
BRPI0720625A2
(pt)
|
2006-12-22 |
2014-03-25 |
Schering Corp |
Derivados de indol de 4,5-anel anulados e métodos de uso dos mesmos
|
AU2007339386B8
(en)
|
2006-12-22 |
2013-12-05 |
Merck Sharp & Dohme Corp. |
4, 5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections
|
AU2008212758B2
(en)
|
2007-02-08 |
2014-01-30 |
Medivir Ab |
Pyrimidine substituted macrocyclic HCV inhibitors
|
EP2117537A1
(fr)
*
|
2007-02-09 |
2009-11-18 |
Irm Llc |
Composés et compositions servant d'inhibiteurs de protéase d'activation de canaux
|
CA2679426A1
(fr)
|
2007-02-27 |
2008-09-04 |
Luc Farmer |
Inhibiteurs de serine proteases
|
AP2009004960A0
(en)
*
|
2007-02-27 |
2009-08-31 |
Vertex Pharma |
Co-crystals and pharmaceutical compositions comprising the same
|
BRPI0808089A2
(pt)
|
2007-02-28 |
2014-07-15 |
Conatus Pharmaceuticals Inc |
Método para tratar uma doença do fígado, para diminuir um nível elevado de uma enzima do fígado, para inibir uma cascata de sinalização de tnf-alfa e uma cascata de sinalização de alfa-faz, para reduzir um dano ao fígado, para suprimir a apoptose excessiva em uma célula de fígado, e para inibir a replicação do vírus da hepatite c.
|
WO2008106167A1
(fr)
*
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Polythérapie incluant des inhibiteurs de métalloprotéinases matricielles et des inhibiteurs de caspases pour le traitement de maladies hépatiques
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
CA2686051A1
(fr)
|
2007-05-04 |
2008-11-13 |
Vertex Pharmaceuticals Incorporated |
Therapie combinee pour le traitement d'une infection par le vhc
|
CA2691442C
(fr)
|
2007-06-29 |
2014-01-21 |
Gilead Sciences, Inc. |
Composes antiviraux
|
CN101801925A
(zh)
|
2007-06-29 |
2010-08-11 |
吉里德科学公司 |
抗病毒组合物
|
CN101842353A
(zh)
|
2007-08-29 |
2010-09-22 |
先灵公司 |
用于治疗病毒感染的2,3-取代的吲哚衍生物
|
EP2408761B1
(fr)
|
2007-08-29 |
2014-01-01 |
Merck Sharp & Dohme Corp. |
Dérivés d'indole substitués et procédés d'utilisation associés
|
CA2697500A1
(fr)
|
2007-08-29 |
2009-03-12 |
Schering Corporation |
Derives d'azaindoles substitues en 2 et 3 destines au traitement d'infections virales
|
EP2436682A1
(fr)
*
|
2007-08-30 |
2012-04-04 |
Vertex Pharmceuticals Incorporated |
Co-cristaux et compositions pharmaceutiques les comprenant
|
GB0718575D0
(en)
|
2007-09-24 |
2007-10-31 |
Angeletti P Ist Richerche Bio |
Nucleoside derivatives as inhibitors of viral polymerases
|
US8367617B2
(en)
|
2007-10-04 |
2013-02-05 |
Onyx Therapeutics, Inc. |
Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
|
CA2705586A1
(fr)
|
2007-11-16 |
2009-05-22 |
Schering Corporation |
Derives d'indole a substitution heterocyclique en position 3 et leurs procedes d'utilisation
|
CA2705587A1
(fr)
|
2007-11-16 |
2009-05-22 |
Schering Corporation |
Derives d'indole a substitution par aminosulfonyle en position 3 et leurs procedes d'utilisation
|
US8202996B2
(en)
|
2007-12-21 |
2012-06-19 |
Bristol-Myers Squibb Company |
Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
|
CN101977915B
(zh)
|
2008-02-04 |
2014-08-13 |
埃迪尼克斯医药公司 |
大环丝氨酸蛋白酶抑制剂
|
TW200946541A
(en)
|
2008-03-27 |
2009-11-16 |
Idenix Pharmaceuticals Inc |
Solid forms of an anti-HIV phosphoindole compound
|
US8163921B2
(en)
|
2008-04-16 |
2012-04-24 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
JP5529120B2
(ja)
|
2008-05-29 |
2014-06-25 |
ブリストル−マイヤーズ スクイブ カンパニー |
C型肝炎ウイルス阻害剤
|
US7964560B2
(en)
|
2008-05-29 |
2011-06-21 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
AR072088A1
(es)
|
2008-06-13 |
2010-08-04 |
Schering Corp |
Derivados de indol triciclicos y sus metodos de uso
|
JP2011526893A
(ja)
|
2008-07-02 |
2011-10-20 |
イデニク プハルマセウティカルス,インコーポレイテッド |
ウイルス感染の治療のための化合物、及び医薬組成物
|
TWI409265B
(zh)
|
2008-08-20 |
2013-09-21 |
Merck Sharp & Dohme |
經取代之吡啶及嘧啶衍生物及彼等於治療病毒感染之用途
|
WO2010022126A1
(fr)
|
2008-08-20 |
2010-02-25 |
Schering Corporation |
Dérivés de pyridine et pyrimidine substituées par azo et leur utilisation dans le traitement d'infections virales
|
AR072939A1
(es)
|
2008-08-20 |
2010-09-29 |
Schering Corp |
Derivados de piridina y pirimidina sustituidas con etenilo y su uso en el tratamiento de infecciones virales
|
CA2734487A1
(fr)
|
2008-08-20 |
2010-02-25 |
Southern Research Institute |
Derives de pyridine et de pyrimidine a substitution ethylyle et leur utilisation dans le traitement d'infections virales
|
US8207341B2
(en)
|
2008-09-04 |
2012-06-26 |
Bristol-Myers Squibb Company |
Process or synthesizing substituted isoquinolines
|
US8563505B2
(en)
|
2008-09-29 |
2013-10-22 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8044087B2
(en)
|
2008-09-29 |
2011-10-25 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2010039801A2
(fr)
|
2008-10-02 |
2010-04-08 |
The J. David Gladstone Institutes |
Méthodes de traitement d’une infection par le virus de l’hépatite c
|
EP3090737A1
(fr)
|
2008-10-21 |
2016-11-09 |
Onyx Therapeutics, Inc. |
Thérapie de combinaison avec peptides d'époxycétones
|
CA2745119A1
(fr)
|
2008-12-03 |
2010-06-10 |
Presidio Pharmaceuticals, Inc. |
Inhibiteurs du virus de l'hepatite c de type ns5a
|
CN104163816A
(zh)
|
2008-12-03 |
2014-11-26 |
普雷西迪奥制药公司 |
Hcv ns5a的抑制剂
|
US8283310B2
(en)
|
2008-12-15 |
2012-10-09 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US8914351B2
(en)
|
2008-12-16 |
2014-12-16 |
Clinton A. Krislov |
Method and system for secure automated document registration from social media networks
|
US8589372B2
(en)
|
2008-12-16 |
2013-11-19 |
Clinton A. Krislov |
Method and system for automated document registration with cloud computing
|
MX2011006631A
(es)
*
|
2008-12-19 |
2011-09-06 |
Gilead Sciences Inc |
Inhibidores de proteasa ns3 del virus hcv.
|
US8551973B2
(en)
|
2008-12-23 |
2013-10-08 |
Gilead Pharmasset Llc |
Nucleoside analogs
|
AU2009329867B2
(en)
|
2008-12-23 |
2015-01-29 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
TW201031675A
(en)
|
2008-12-23 |
2010-09-01 |
Pharmasset Inc |
Synthesis of purine nucleosides
|
US8102720B2
(en)
*
|
2009-02-02 |
2012-01-24 |
Qualcomm Incorporated |
System and method of pulse generation
|
WO2010101967A2
(fr)
|
2009-03-04 |
2010-09-10 |
Idenix Pharmaceuticals, Inc. |
Inhibiteurs de phosphothiophène et phosphothiazole vhc polymérase
|
JP2012520884A
(ja)
|
2009-03-18 |
2012-09-10 |
ザ ボード オブ トラスティーズ オブ ザ リランド スタンフォード ジュニア ユニバーシティー |
フラビウイルス科ウイルス感染症を治療する方法および組成物
|
AR075899A1
(es)
|
2009-03-20 |
2011-05-04 |
Onyx Therapeutics Inc |
Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
|
KR20110131312A
(ko)
|
2009-03-27 |
2011-12-06 |
프레시디오 파마슈티칼스, 인코포레이티드 |
융합된 고리 c형 간염 억제제
|
WO2010117936A1
(fr)
|
2009-04-06 |
2010-10-14 |
Schering Corporation |
Associations d'un inhibiteur du virus de l'hépatite c (vhc), tels des dérivés pyrroliques bicycliques, et d'un agent thérapeutique
|
EP2416765B1
(fr)
|
2009-04-06 |
2016-03-30 |
PTC Therapeutics, Inc. |
Inhibiteur de vhc et combinaisons d'agent thérapeutique
|
WO2010118078A1
(fr)
|
2009-04-08 |
2010-10-14 |
Idenix Pharmaceuticals, Inc. |
Inhibiteurs macrocycliques de la sérine protéase
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
US20110182850A1
(en)
|
2009-04-10 |
2011-07-28 |
Trixi Brandl |
Organic compounds and their uses
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
TWI576352B
(zh)
|
2009-05-20 |
2017-04-01 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
WO2010138791A1
(fr)
|
2009-05-29 |
2010-12-02 |
Schering Corporation |
Composés antiviraux de trois fractions d'aryle liées pour traiter des maladies telles que l'hépatite c
|
JP2013501068A
(ja)
|
2009-08-05 |
2013-01-10 |
アイディニックス ファーマシューティカルズ インコーポレイテッド |
大環状セリンプロテアーゼ阻害剤
|
AU2009352688B2
(en)
|
2009-09-15 |
2014-04-17 |
Taigen Biotechnology Co., Ltd. |
HCV protease inhibitors
|
US8853147B2
(en)
|
2009-11-13 |
2014-10-07 |
Onyx Therapeutics, Inc. |
Use of peptide epoxyketones for metastasis suppression
|
WO2011063076A1
(fr)
|
2009-11-19 |
2011-05-26 |
Itherx Pharmaceuticals, Inc. |
Méthodes de traitement du virus de l'hépatite c avec des composés d'oxo-acétamide
|
EP2504329A1
(fr)
|
2009-11-25 |
2012-10-03 |
Vertex Pharmaceuticals Incorporated |
Dérivés d'acide 5-alcynyl-thiophène-2-carboxylique et leur utilisation pour traiter ou prévenir des infections à flavivirus
|
WO2011066241A1
(fr)
|
2009-11-25 |
2011-06-03 |
Schering Corporation |
Composés tricycliques fusionnés et leurs dérivés utiles pour le traitement de maladies virales
|
NZ600608A
(en)
|
2009-12-18 |
2015-01-30 |
Idenix Pharmaceuticals Inc |
5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
|
US20130156731A1
(en)
|
2009-12-22 |
2013-06-20 |
Kevin X. Chen |
Fused tricyclic compounds and methods of use thereof for the treatment of viral diseas
|
JP5783659B2
(ja)
|
2009-12-22 |
2015-09-24 |
セファロン、インク. |
プロテアソーム阻害剤およびその調製、精製および使用のための方法
|
MX2012007420A
(es)
|
2009-12-24 |
2012-07-23 |
Vertex Pharma |
Analogos para el tratamiento o prevencion de infecciones de flavivirus.
|
PL2528922T3
(pl)
|
2010-01-27 |
2018-01-31 |
Ab Pharma Ltd |
Związki poliheterocykliczne jako inhibitory hcv
|
US9433621B2
(en)
|
2010-02-18 |
2016-09-06 |
Merck Sharp & Dohme Corp. |
Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
|
JP6042724B2
(ja)
|
2010-03-01 |
2016-12-14 |
オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. |
イムノプロテアソーム阻害のための化合物
|
WO2011112516A1
(fr)
|
2010-03-08 |
2011-09-15 |
Ico Therapeutics Inc. |
Traitement et prévention de l'infection par le virus de l'hépatite c en utilisant des oligonucléotides antisens de la kinase c-raf
|
ES2558554T3
(es)
|
2010-03-09 |
2016-02-05 |
Merck Sharp & Dohme Corp. |
Compuestos de sililo tricíclicos condensados y métodos de uso de los mismos para el tratamiento de enfermedades víricas
|
AU2011232331A1
(en)
|
2010-03-24 |
2012-10-11 |
Vertex Pharmaceuticals Incorporated |
Analogues for the treatment or prevention of Flavivirus infections
|
CA2794181A1
(fr)
|
2010-03-24 |
2011-09-29 |
Vertex Pharmaceuticals Incorporated |
Analogues pour traiter ou prevenir les infections a flavivirus
|
WO2011119860A1
(fr)
|
2010-03-24 |
2011-09-29 |
Vertex Pharmaceuticals Incorporated |
Analogues pour traiter ou prévenir les infections à flavivirus
|
WO2011119858A1
(fr)
|
2010-03-24 |
2011-09-29 |
Vertex Pharmaceuticals Incorporated |
Analogues destinés au traitement ou à la prévention d'infections à flavivirus
|
HUE026235T2
(en)
|
2010-03-31 |
2016-06-28 |
Gilead Pharmasset Llc |
Crystalline (S) -isopropyl 2 - (((S) - (((2R, 3R, 4R, 5R) -5- (2,4-dioxo-3,4-dihydropyrimidin-1 (2H) -IL) - 4-Fluoro-3-hydroxy-4-methyltetrahydrofuran-2-IL) methoxy) (phenoxy) phosphoryl) amino) propanoate
|
CN102917585A
(zh)
|
2010-04-01 |
2013-02-06 |
埃迪尼克斯医药公司 |
用于治疗病毒感染的化合物和药物组合物
|
EP2555621A4
(fr)
|
2010-04-07 |
2014-07-02 |
Onyx Therapeutics Inc |
Inhibiteur d'immunoprotéasome de peptide époxycétone cristallin
|
US8877707B2
(en)
|
2010-05-24 |
2014-11-04 |
Presidio Pharmaceuticals, Inc. |
Inhibitors of HCV NS5A
|
WO2011156545A1
(fr)
|
2010-06-09 |
2011-12-15 |
Vertex Pharmaceuticals Incorporated |
Modèle dynamique viral pour une polythérapie contre le vhc
|
US20130157258A1
(en)
|
2010-06-15 |
2013-06-20 |
Vertex Pharmaceuticals Incorporated |
Hcv ns5b protease mutants
|
CA2803248A1
(fr)
|
2010-06-28 |
2012-01-12 |
Vertex Pharmaceuticals Incorporated |
Composes et methodes pour le traitement ou la prevention d'infections par flavivirus
|
JP2013531011A
(ja)
|
2010-06-28 |
2013-08-01 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
フラビウイルス感染の処置または予防のための化合物および方法
|
WO2012006070A1
(fr)
|
2010-06-28 |
2012-01-12 |
Vertex Pharmaceuticals Incorporated |
Composés et méthodes de traitement ou de prévention d'infections à flavivirus
|
WO2012018534A2
(fr)
|
2010-07-26 |
2012-02-09 |
Schering Corporation |
Composés de biphénylène substitué et procédés d'utilisation desdits composés pour le traitement de maladies virales
|
WO2012020036A1
(fr)
|
2010-08-13 |
2012-02-16 |
F. Hoffmann-La Roche Ag |
Inhibiteurs du virus de l'hépatite c
|
JP2013534249A
(ja)
|
2010-08-17 |
2013-09-02 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
フラビウイルス科ウイルス感染の処置または予防のための化合物および方法
|
EP2621279B1
(fr)
|
2010-09-29 |
2018-04-04 |
Merck Sharp & Dohme Corp. |
Dérivés tétracycliques condensés et procédés d'utilisation de ceux-ci dans le traitement de maladies virales
|
BR112013008510A2
(pt)
|
2010-10-08 |
2016-07-05 |
Novartis Ag |
vitamina e formulações de inibidores de sulfamida ns3
|
US8729014B2
(en)
|
2010-11-01 |
2014-05-20 |
Rfs Pharma, Llc |
Specific HCV NS3 protease inhibitors
|
TW201242974A
(en)
|
2010-11-30 |
2012-11-01 |
Gilead Pharmasset Llc |
Compounds
|
AR085352A1
(es)
|
2011-02-10 |
2013-09-25 |
Idenix Pharmaceuticals Inc |
Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
|
WO2012107589A1
(fr)
|
2011-02-11 |
2012-08-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Méthodes et compositions pharmaceutiques pour le traitement et la prévention des infections à vhc
|
WO2012123298A1
(fr)
|
2011-03-11 |
2012-09-20 |
F. Hoffmann-La Roche Ag |
Composés antiviraux
|
WO2012154321A1
(fr)
|
2011-03-31 |
2012-11-15 |
Idenix Pharmaceuticals, Inc. |
Composés et compositions pharmaceutiques pour le traitement d'infections virales
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
WO2012142075A1
(fr)
|
2011-04-13 |
2012-10-18 |
Merck Sharp & Dohme Corp. |
Dérivés de nucléosides à substitution 2'-azido et leurs procédés d'utilisation pour le traitement de maladies virales
|
US8957203B2
(en)
|
2011-05-05 |
2015-02-17 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
US10501493B2
(en)
|
2011-05-27 |
2019-12-10 |
Rqx Pharmaceuticals, Inc. |
Broad spectrum antibiotics
|
US8691757B2
(en)
|
2011-06-15 |
2014-04-08 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
CA2857705A1
(fr)
|
2011-06-16 |
2012-12-20 |
AB Pharma Ltd. |
Compose heterocyclique macrocyclique pour l'inhibition du virus de l'hepatite c, sa preparation et ses applications
|
BR112013032188A2
(pt)
|
2011-06-23 |
2016-12-20 |
Digna Biotech Sl |
composição, produto e método para tratar pacientes com hepatite c crônica
|
WO2012175581A1
(fr)
|
2011-06-24 |
2012-12-27 |
F. Hoffmann-La Roche Ag |
Composés antiviraux
|
CN102807607B
(zh)
*
|
2011-07-22 |
2013-10-23 |
爱博新药研发(上海)有限公司 |
抑制丙肝病毒的稠环杂环类化合物、其中间体及其应用
|
WO2013016499A1
(fr)
|
2011-07-26 |
2013-01-31 |
Vertex Pharmaceuticals Incorporated |
Procédés de préparation de composés du thiophène
|
AU2012286853A1
(en)
|
2011-07-26 |
2013-05-02 |
Vertex Pharmaceuticals Incorporated |
Thiophene compounds
|
WO2013033899A1
(fr)
|
2011-09-08 |
2013-03-14 |
Merck Sharp & Dohme Corp. |
Composés benzofuranes substitués et leur procédés d'utilisation pour le traitement de maladies virales
|
WO2013033900A1
(fr)
|
2011-09-08 |
2013-03-14 |
Merck Sharp & Dohme Corp. |
Composés hétérocycliques tétracycliques et leurs procédés d'utilisation pour le traitement de maladies virales
|
WO2013033901A1
(fr)
|
2011-09-08 |
2013-03-14 |
Merck Sharp & Dohme Corp. |
Dérivés benzofuranes substitués par un hétérocycle et leurs procédés d'utilisation pour le traitement de maladies virales
|
EP2755985B1
(fr)
|
2011-09-12 |
2017-11-01 |
Idenix Pharmaceuticals LLC |
Composés et compositions pharmaceutiques pour le traitement d'infections virales
|
US9403863B2
(en)
|
2011-09-12 |
2016-08-02 |
Idenix Pharmaceuticals Llc |
Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
|
WO2013039876A1
(fr)
|
2011-09-14 |
2013-03-21 |
Merck Sharp & Dohme Corp. |
Composés hétérocycliques contenant un silyle et méthodes d'utilisation desdits composés pour traiter les maladies virales
|
US9180193B2
(en)
|
2011-10-10 |
2015-11-10 |
Hoffmann-La Roche Inc. |
Antiviral compounds
|
US8507460B2
(en)
|
2011-10-14 |
2013-08-13 |
Idenix Pharmaceuticals, Inc. |
Substituted 3′,5′-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
|
US20130123276A1
(en)
|
2011-11-14 |
2013-05-16 |
Sven Ruf |
Use of telaprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
CN104185420B
(zh)
|
2011-11-30 |
2017-06-09 |
埃默里大学 |
用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂
|
US9364484B2
(en)
|
2011-12-06 |
2016-06-14 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and compositions for treating viral diseases
|
JP5923181B2
(ja)
|
2011-12-16 |
2016-05-24 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Hcvns5aの阻害剤
|
JP5982007B2
(ja)
|
2011-12-20 |
2016-08-31 |
リボサイエンス・エルエルシー |
Hcvrna複製の阻害薬としての2’,4’−ジフルオロ−2’−メチル置換されたヌクレオシド誘導体
|
KR101687084B1
(ko)
|
2011-12-20 |
2016-12-15 |
리보사이언스 엘엘씨 |
Hcv rna 복제의 억제제로서 4'-아지도, 3'-플루오로 치환된 뉴클레오시드 유도체
|
US8809354B2
(en)
|
2011-12-31 |
2014-08-19 |
Sheikh Riazuddin |
3-amino-2-(4-nitrophenyl)-4-(3H)-quinazolinone or derivatives thereof for treating or preventing antiviral infections
|
WO2013106689A1
(fr)
|
2012-01-12 |
2013-07-18 |
Ref Pharma, Llc. |
Inhibiteurs de la protéase ns3 du vhc
|
WO2013133927A1
(fr)
|
2012-02-13 |
2013-09-12 |
Idenix Pharmaceuticals, Inc. |
Compositions pharmaceutiques de 2'-c-méthyl-guanosine, 5'-[2-[(3-hydroxy-2,2-diméthyl-1-oxopropyl)thio]éthyl n-(phénylméthyl)phosphoramidate]
|
EA201491511A1
(ru)
*
|
2012-02-16 |
2014-12-30 |
АрКьюИкс ФАРМАСЬЮТИКАЛС, ИНК. |
Линейные пептидные антибиотики
|
BR112014015582A8
(pt)
*
|
2012-02-24 |
2017-07-04 |
Hoffmann La Roche |
compostos antivirais
|
NZ630805A
(en)
|
2012-03-22 |
2016-01-29 |
Alios Biopharma Inc |
Pharmaceutical combinations comprising a thionucleotide analog
|
US9296778B2
(en)
|
2012-05-22 |
2016-03-29 |
Idenix Pharmaceuticals, Inc. |
3′,5′-cyclic phosphate prodrugs for HCV infection
|
US9109001B2
(en)
|
2012-05-22 |
2015-08-18 |
Idenix Pharmaceuticals, Inc. |
3′,5′-cyclic phosphoramidate prodrugs for HCV infection
|
JP6165848B2
(ja)
|
2012-05-22 |
2017-07-19 |
イデニク ファーマシューティカルズ エルエルシー |
肝疾患のためのd−アミノ酸化合物
|
US20140010783A1
(en)
|
2012-07-06 |
2014-01-09 |
Hoffmann-La Roche Inc. |
Antiviral compounds
|
TW201414751A
(zh)
|
2012-07-09 |
2014-04-16 |
歐尼克斯治療公司 |
肽環氧酮蛋白酶抑制劑之前驅藥物
|
WO2014053533A1
(fr)
|
2012-10-05 |
2014-04-10 |
Sanofi |
Utilisation de dérivés substitués de l'acide 3-hétéroaroylamino-propionique en tant que produits pharmaceutiques destinés à la prévention/au traitement de la fibrillation auriculaire
|
AU2013329521B2
(en)
|
2012-10-08 |
2018-04-19 |
Centre National De La Recherche Scientifique |
2'-chloro nucleoside analogs for HCV infection
|
LT2909205T
(lt)
|
2012-10-19 |
2016-12-27 |
Bristol-Myers Squibb Company |
9-metilpakeistieji heksadekahidrociklopropa(e)pirolo (1,2-a)(1,4)diazaciklopentadecinilkarbamato dariniai, kaip nestruktūrinės 3 (ns3) proteazės inhibitoriai, skirti hepatito c viruso infekcijų gydymui
|
WO2014063019A1
(fr)
|
2012-10-19 |
2014-04-24 |
Idenix Pharmaceuticals, Inc. |
Composés dinucléotides contre une infection par le vhc
|
EP2909222B1
(fr)
|
2012-10-22 |
2021-05-26 |
Idenix Pharmaceuticals LLC |
Nucléosides 2', 4'-pontés pour l'infection par le vhc
|
US10260089B2
(en)
|
2012-10-29 |
2019-04-16 |
The Research Foundation Of The State University Of New York |
Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
|
EP2914598B1
(fr)
|
2012-11-02 |
2017-10-18 |
Bristol-Myers Squibb Company |
Inhibiteurs du virus de l'hépatite c
|
WO2014070964A1
(fr)
|
2012-11-02 |
2014-05-08 |
Bristol-Myers Squibb Company |
Inhibiteurs du virus de l'hépatite c
|
US9643999B2
(en)
|
2012-11-02 |
2017-05-09 |
Bristol-Myers Squibb Company |
Hepatitis C virus inhibitors
|
WO2014070974A1
(fr)
|
2012-11-05 |
2014-05-08 |
Bristol-Myers Squibb Company |
Inhibiteurs du virus de l'hépatite c
|
EP2920195A1
(fr)
|
2012-11-14 |
2015-09-23 |
IDENIX Pharmaceuticals, Inc. |
Ester de d-alanine d'analogue de rp-nucléoside
|
WO2014078436A1
(fr)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
Ester de d-alanine d'analogue de sp-nucléoside
|
WO2014099941A1
(fr)
|
2012-12-19 |
2014-06-26 |
Idenix Pharmaceuticals, Inc. |
4'-fluoro-nucléosides pour le traitement du vhc
|
BR112015017414A2
(pt)
|
2013-01-23 |
2017-07-11 |
Hoffmann La Roche |
derivados de triazol antivirais
|
WO2014134251A1
(fr)
|
2013-02-28 |
2014-09-04 |
Vertex Pharmaceuticals Incorporated |
Compositions pharmaceutiques
|
US9339541B2
(en)
|
2013-03-04 |
2016-05-17 |
Merck Sharp & Dohme Corp. |
Thiophosphate nucleosides for the treatment of HCV
|
WO2014137926A1
(fr)
|
2013-03-04 |
2014-09-12 |
Idenix Pharmaceuticals, Inc. |
3'-désoxynucléosides utilisables en vue du traitement d'une infection par le vhc
|
BR112015021429A2
(pt)
|
2013-03-05 |
2017-07-18 |
Hoffmann La Roche |
compostos antivirais
|
CN105164148A
(zh)
|
2013-03-07 |
2015-12-16 |
百时美施贵宝公司 |
丙型肝炎病毒抑制剂
|
US9187515B2
(en)
|
2013-04-01 |
2015-11-17 |
Idenix Pharmaceuticals Llc |
2′,4′-fluoro nucleosides for the treatment of HCV
|
JP2016519146A
(ja)
|
2013-05-16 |
2016-06-30 |
リボサイエンス・エルエルシー |
4’−アジド,3’−デオキシ−3’−フルオロ置換ヌクレオシド誘導体
|
US20180200280A1
(en)
|
2013-05-16 |
2018-07-19 |
Riboscience Llc |
4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
|
MX2015015782A
(es)
|
2013-05-16 |
2016-06-02 |
Riboscience Llc |
Derivados de nucleosido 4'-fluoro-2'-metil sustituido.
|
WO2014197578A1
(fr)
|
2013-06-05 |
2014-12-11 |
Idenix Pharmaceuticals, Inc. |
1',4'-thio nucléosides pour le traitement du virus de l'hépatite c (vhc)
|
EP3027636B1
(fr)
|
2013-08-01 |
2022-01-05 |
Idenix Pharmaceuticals LLC |
Phosphoramidate de d-acides aminés pronucleotidiques dérivés de pyrimidine halogenée pour des maladies du foie
|
RU2016107436A
(ru)
*
|
2013-08-14 |
2017-09-19 |
АрКьюЭкс ФАРМАСЬЮТИКЛС, ИНК. |
Линейные пептидные антибиотики
|
MX2016002185A
(es)
|
2013-08-27 |
2016-06-06 |
Gilead Pharmasset Llc |
Formulacion combinada de dos compuestos antivirales.
|
US20160229866A1
(en)
|
2013-09-20 |
2016-08-11 |
Idenix Pharmaceuticals Inc. |
Hepatitis c virus inhibitors
|
WO2015061683A1
(fr)
|
2013-10-25 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
Pronucléotides thiophosphoramidates à acide aminé d et pronucléotides thiophosphoramidates à d-analine de composés de nucléoside utiles pour le traitement du vhc
|
US10167298B2
(en)
|
2013-10-30 |
2019-01-01 |
Merck Sharp & Dohme Corp. |
Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof
|
WO2015066370A1
(fr)
|
2013-11-01 |
2015-05-07 |
Idenix Pharmaceuticals, Inc. |
Pronucléotides phosphoramidates de d-alanine de composés de nucléoside 2'-méthyl 2'-fluoro guanosine dans le traitement du vhc
|
US20170198005A1
(en)
|
2013-11-27 |
2017-07-13 |
Idenix Pharmaceuticals Llc |
2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
|
US10683321B2
(en)
|
2013-12-18 |
2020-06-16 |
Idenix Pharmaceuticals Llc |
4′-or nucleosides for the treatment of HCV
|
EP2899207A1
(fr)
|
2014-01-28 |
2015-07-29 |
Amikana.Biologics |
Nouveau procédé pour tester l'inhibition de la protéase du HCV
|
US20170135990A1
(en)
|
2014-03-05 |
2017-05-18 |
Idenix Pharmaceuticals Llc |
Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
|
EP3113763A1
(fr)
|
2014-03-05 |
2017-01-11 |
Idenix Pharmaceuticals LLC |
Formes solides de promédicaments de 2'-chloro-2'-méthyl uridine pour lutter contre le vhc
|
WO2015134560A1
(fr)
|
2014-03-05 |
2015-09-11 |
Idenix Pharmaceuticals, Inc. |
Formes solides d'un composé inhibiteur des virus de la famille des flaviviridae et sels de celui-ci
|
WO2015161137A1
(fr)
|
2014-04-16 |
2015-10-22 |
Idenix Pharmaceuticals, Inc. |
Nucléosides méthyle ou alcynyle substitués en position 3 pour le traitement du virus de l'hépatite c
|
JP6873993B2
(ja)
|
2015-11-20 |
2021-05-19 |
アールキューエックス ファーマシューティカルズ,インク. |
大環状広域抗生物質
|
US10526315B2
(en)
|
2016-06-21 |
2020-01-07 |
Orion Ophthalmology LLC |
Carbocyclic prolinamide derivatives
|
EA201990069A1
(ru)
|
2016-06-21 |
2019-06-28 |
ОРИОН ОФТАЛМОЛОДЖИ ЭлЭлСи |
Производные гетероциклического пролинамида
|
WO2017222917A1
(fr)
|
2016-06-21 |
2017-12-28 |
Inception 4, Inc. |
Dérivés de prolinamide aliphatique
|
WO2018036942A1
(fr)
*
|
2016-08-23 |
2018-03-01 |
F. Hoffmann-La Roche Ag |
Nouveaux dérivés de difluorocétamide en tant qu'inhibiteurs de htra1
|
CN110709096B
(zh)
|
2017-05-05 |
2023-10-31 |
泽兰德制药公司 |
细胞间隙连接通讯调节剂及其在糖尿病性眼病治疗中的应用
|
GB2563396B
(en)
*
|
2017-06-12 |
2020-09-23 |
Ustav Organicke Chemie A Biochemie Av Cr V V I |
Inhibitors of Rhomboid Intramembrane Proteases
|
WO2019060740A1
(fr)
|
2017-09-21 |
2019-03-28 |
Riboscience Llc |
Dérivés nucléosidiques à substitution 4'-fluoro-2'-méthyle utilisés comme inhibiteurs de la réplication de l'arn du vhc
|
JP2022510407A
(ja)
|
2018-12-04 |
2022-01-26 |
ブリストル-マイヤーズ スクイブ カンパニー |
多重反応同位体分子種反応モニタリングによる、サンプル内検量線を用いた分析方法
|
BR112021024010A2
(pt)
|
2019-05-28 |
2022-05-17 |
Hoffmann La Roche |
Antibióticos macrocíclicos de amplo espectro
|